Phase 3 Trial of Ifinatamab Deruxtecan Begins in Advanced Prostate Cancer
Phase 3 Trial Launches for Ifinatamab Deruxtecan in Advanced Prostate Cancer Patients Daiichi Sankyo and Merck have announced the initiation of IDeate-Prostate01, a global Phase 3 clinical trial evaluating the…
AbbVie: Atogepant Outperforms Topiramate in Phase 3 Migraine Study
AbbVie Reports Strong Phase 3 Results for Atogepant, Demonstrating Superiority Over Topiramate in Migraine Prevention AbbVie, a leading global biopharmaceutical company, has announced promising topline results from its pivotal Phase…
Teva and Fosun Partner to Develop Novel Anti-PD1-IL2 Immunotherapy
Teva and Fosun Pharma Forge Strategic Partnership to Develop and Commercialize Innovative Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology Teva Pharmaceutical Industries Ltd.and Shanghai Fosun Pharmaceutical (Group) Co., Ltd.today announced a significant…
BioMarin Boosts Enzyme Therapy Business with Inozyme Acquisition
BioMarin Boosts Enzyme Therapy Business with Inozyme Acquisition BioMarin Pharmaceutical and Inozyme Pharma today announced that BioMarin has entered into a definitive agreement to acquire Inozyme for $4.00 per share…
Extel 2025: WuXi AppTec Recognized with Top Honors
WuXi AppTec Recognized Among Top 10 “Most Honored Companies” in Extel 2025 Asia Executive Team Rankings, Continuing its Global Leadership in Innovation and Drug Discovery Services WuXi AppTec, a leading…
FDA Approves CSL’s Andembry First Once-Monthly Prophylactic HAE Treatment Targeting Factor XIIa
FDA Approves ANDEMBRY (garadacimab-gxii) The First Once-Monthly Prophylactic HAE Therapy Targeting Factor XIIa CSL a leading biotechnology company with a strong track record of developing innovative medicines for patients with…
BMS Presents Transcend FL Data: Breyanzi Shows Durable Responses in Marginal Zone Lymphoma
Bristol Myers Squibb Presents Positive Transcend FL Data Highlighting Durable Responses with Breyanzi in Relapsed or Refractory Marginal Zone Lymphoma Bristol Myers Squibb today announced the first disclosure of the…
Roche Advances Prasinezumab to Phase III for Early Parkinson’s Disease
Roche Advances Prasinezumab into Phase III Development for Early-Stage Parkinson’s Disease Roche today announced its decision to move forward with Phase III clinical development of prasinezumab — its investigational, humanized…
Lilly Offers All Zepbound Doses via LillyDirect Self-Pay Pharmacy
Lilly to Expand Access to Zepbound: All Approved Doses Now Available in Vials Through LillyDirect’s Self-Pay Pharmacy Solutions Eli Lilly and Company today made a significant announcement aimed at improving…
Intellia Reports Positive 3-Year Phase 1 Data for Lonvo-z in Hereditary Angioedema
Intellia Therapeutics Reports Positive 3-Year Phase 1 Data for Lonvo-z in Hereditary Angioedema — Highlights Durable Benefit and Safety Intellia Therapeutics, a leading clinical-stage genome-editing biotechnology company, today presented updated…
Sarepta Strengthens ELEVIDYS Safety Measures for Non-Ambulatory Duchenne Patients
Sarepta Takes Action to Strengthen ELEVIDYS Safety Measures in Non-Ambulatory Duchenne Patients Sarepta Therapeutic a leading innovator in precision genetic medicine for rare disorders, today provided a significant safety update…
QIAGEN and Incyte Partner on Companion Dx for Mutant CALR MPNs
QIAGEN and Incyte Forge Global Collaboration to Develop Companion Diagnostic Panel for Patients With Mutant CALR-Positive Myeloproliferative Neoplasms QIAGEN N.V. and Incyte today announced a significant new collaboration aimed at…